Free tool
FAERS Monitor: Lumisight
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214511 or its brand name (Lumisight, Pegulicianine Acetate). Reports on generic versions are filed under their own applications.
Reports
8
Serious
4
50% of reports
Hospitalization
2
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- flushing4
- hypersensitivity3
- paraesthesia3
- anaphylactic shock2
- back pain2
- cardiac arrest2
- cough2
- feeling hot2
- hyperhidrosis2
- malaise2
- nausea2
- acute kidney injury1
- acute myocardial infarction1
- anxiety1
- blood pressure systolic increased1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 2 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,151 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anaphylactic shock | 2 | 204.0 | 61.4 | 227 |
| blood pressure systolic increased | 1 | 134.8 | 21.6 | 33 |
| flushingSignal | 4 | 103.5 | 51.7 | 311 |
| acute myocardial infarction | 1 | 89.2 | 14.3 | 21 |
| feeling hot | 2 | 85.8 | 25.8 | 94 |
| cardiac arrest | 2 | 63.7 | 19.2 | 69 |
| paraesthesiaSignal | 3 | 50.1 | 20.5 | 100 |
| hypersensitivitySignal | 3 | 42.5 | 17.4 | 84 |
| hyperhidrosis | 2 | 40.8 | 12.3 | 43 |
| back pain | 2 | 22.6 | 6.8 | 23 |
| cough | 2 | 18.8 | 5.6 | 18 |
| acute kidney injury | 1 | 17.2 | 2.7 | 3 |
| malaise | 2 | 12.0 | 3.6 | 11 |
| anxiety | 1 | 9.2 | 1.5 | 1 |
| nausea | 2 | 6.6 | 2.0 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.